Avadel Pharmaceuticals Dividenda 2024

Detalji o dividendama

Razumevanje dividendnih isplata od Avadel Pharmaceuticals

Dividende od Avadel Pharmaceuticals su deo profita kompanije koji se distribuira akcionarima. One su ključni indikator finansijskog zdravlja kompanije i atraktivnosti za investitore. Dividende pružaju investitorima stabilan izvor prihoda, pored dobiti koja se možda može ostvariti prodajom akcija po višoj ceni od kupovne.

Poređenje iz godine u godinu

Analiza isplata dividendi od Avadel Pharmaceuticals tokom godina može istaći profitabilnost i stabilnost kompanije. Konstantno ili rastuće isplate dividendi mogu ukazivati na finansijski zdravu kompaniju sa predvidivim profitom, dok fluktuacije ili smanjenja dividendi mogu signalizirati osnovne finansijske ili operativne izazove.

Uticaj na investicije

Isplate dividendi od Avadel Pharmaceuticals su suštinski faktor za investitore orijentisane na prihod. Robusna isplata dividendi može povećati privlačnost akcije i pružiti redovni prihod pored potencijalnih kapitalnih dobitaka. Ona može takođe pokazati poverenje kompanije u njene buduće profite i time biti značajan faktor za odlučivanje o investicijama.

Interpretacija fluktuacija dividendi

Promene u dividendama od Avadel Pharmaceuticals mogu proistići iz promena u profitima kompanije, finansijskoj politici ili strategijama reinvestiranja. Povećanje dividendi često signalizira finansijsku stabilnost, dok smanjenje može ukazivati na potrebu da se sačuva gotovina ili da se profiti reinvestiraju radi podsticanja rasta, pri čemu svaki scenario ima različite posledice za investitore.

Avadel Pharmaceuticals Aktienanalyse

Шта ради Avadel Pharmaceuticals?

Avadel Pharmaceuticals PLC is an Irish pharmaceutical company that focuses on the development, manufacturing, and marketing of pharmaceutical products. The company was founded in 1999 under the name Flamel Technologies and was renamed Avadel Pharmaceuticals in 2019 to support its rebranding strategy and expand its activities in the global market. Avadel's business model is based on the discovery and development of therapies for rare diseases and sleep-related disorders, as well as the manufacturing and marketing of generic drugs and specialty products. The company is divided into three main segments: specialty pharmaceuticals, generic pharmaceuticals, and the Pediarix division. Avadel's specialty pharmaceuticals segment focuses on developing drugs for patients with rare diseases such as Prader-Willi syndrome or narcolepsy. An example of an innovative product in this segment is Rekarbri, an ORP medication for the treatment of narcolepsy. It is the first drug in the EU specifically tailored to the specific needs of narcolepsy patients and has improved patients' quality of life. The generic pharmaceuticals segment of Avadel offers high-quality and cost-effective medications that treat commonly prescribed and everyday conditions such as pain, infections, depression, and anxiety disorders. Most products in this segment are manufactured in the USA and are available in many countries worldwide. Avadel's Pediarix division specializes in the development and manufacturing of children's medicines. This includes products for the treatment of attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD). An example of a product from this segment is Reagila, a medication for the treatment of ADHD in children that is known for its improved efficacy and lower risk of side effects. Avadel also has a geographically distributed business structure that allows it to market its products worldwide. The company has a strong presence in the USA and is represented in Europe, Asia, and Australia. It has an impressive research and development infrastructure, including manufacturing facilities and research facilities, that allow it to meet the needs of its customers. Overall, Avadel Pharmaceuticals is a leading pharmaceutical company that focuses on researching new and innovative therapies for patients with rare diseases and sleep-related disorders. The company has demonstrated its ability to bring effective products to the market while maintaining the highest standards in quality assurance and customer service. It is expected that Avadel will continue to grow in the future and introduce new and innovative products to help its customers and patients worldwide. Avadel Pharmaceuticals je jedna od najpopularnijih kompanija na Eulerpool.com.

Često postavljana pitanja o Avadel Pharmaceuticals akciji

Kolika je dividenda koju isplaćuje Avadel Pharmaceuticals?

U poslednjih 12 meseci, Avadel Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Avadel Pharmaceuticals će verovatno isplatiti dividendu od 0 USD.

Kolika je dividendna prinosa za Avadel Pharmaceuticals?

Dividendski prinos od Avadel Pharmaceuticals trenutno iznosi .

Kada Avadel Pharmaceuticals isplaćuje dividendu?

Avadel Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Avadel Pharmaceuticals?

Avadel Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Avadel Pharmaceuticals?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Avadel Pharmaceuticals?

Avadel Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Avadel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Avadel Pharmaceuticals od 1. 10. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 1. 10. 2024..

Kada je Avadel Pharmaceuticals poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 1. 10. 2024..

Kolika je bila dividenda od Avadel Pharmaceuticals u godini 2023?

U godini 2023 kompanija Avadel Pharmaceuticals je isplatila 0 USD kao dividende.

U kojoj valuti Avadel Pharmaceuticals isplaćuje dividendu?

Dividende od Avadel Pharmaceuticals se isplaćuju u USD.